It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Clinically isolated syndrome (CIS) is the earliest clinical episode in multiple sclerosis (MS). Low environmental exposure to UV radiation is implicated in risk of developing MS, and therefore, narrowband UVB phototherapy might delay progression to MS in people with CIS. Twenty individuals with CIS were recruited, and half were randomised to receive 24 sessions of narrowband UVB phototherapy over a period of 8 weeks. Here, the effects of narrowband UVB phototherapy on the frequencies of circulating immune cells and immunoglobulin levels after phototherapy are reported. Peripheral blood samples for all participants were collected at baseline, and 1, 2, 3, 6 and 12 months after enrolment. An extensive panel of leukocyte populations, including subsets of T cells, B cells, monocytes, dendritic cells, and natural killer cells were examined in phototherapy-treated and control participants, and immunoglobulin levels measured in serum. There were significant short-term increases in the frequency of naïve B cells, intermediate monocytes, and fraction III FoxP3+ T regulatory cells, and decreases in switched memory B cells and classical monocytes in phototherapy-treated individuals. Since B cells are increasingly targeted by MS therapies, the effects of narrowband UVB phototherapy in people with MS should be investigated further.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Western Australia, Telethon Kids Institute, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
2 Perron Institute for Neurological and Translational Science, University of Western Australia, Sir Charles Gairdner Hospital, Centre for Neuromuscular and Neurological Disorders, Perth, Australia (GRID:grid.1012.2)
3 St John of God Hospital, St John of God Dermatology Clinic, Perth, Australia (GRID:grid.460013.0)
4 Westmead Institute for Medical Research, University of Sydney, Faculty of Medicine and Health, Westmead, Australia (GRID:grid.460013.0)
5 Australian National University, National Centre for Epidemiology & Population Health, Research School of Population Health, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); University of Western Australia, Centre for Ophthalmology and Visual Science, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
6 University of Western Australia, UWA Medical School and School of Biomedical Sciences, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
7 Westmead Institute for Medical Research, University of Sydney, Faculty of Medicine and Health, Westmead, Australia (GRID:grid.1012.2)
8 Perron Institute for Neurological and Translational Science, University of Western Australia, Sir Charles Gairdner Hospital, Centre for Neuromuscular and Neurological Disorders, Perth, Australia (GRID:grid.1012.2); Institute for Immunology and Infectious Disease, Murdoch University, Perth, Australia (GRID:grid.1025.6) (ISNI:0000 0004 0436 6763)